Çocuklarda Subkutan İmmünglobülin Kullanımı

Yıl 2017, Cilt: 17 Sayı: 4, 146 - 150, 01.10.2017

Manolya Acar Ayper Somer

https://doi.org/10.5222/j.child.2017.146

Öz

İnsan plazma kaynaklı immünglobülinler başta primer immün yetersizlik hastalıkları olmak üzere pek çok hastalı- ğın tedavi seçenekleri arasında yer almaktadır. İmmünglobülin preparatları; intravenöz IV , subkutan SC ya da intramüsküler IM yolla verilebilir. Son yıllar- da subkutan immünglobülin SIG uygulaması, hasta konfo- runun daha yüksek, maliyetinin ve yan etki insidansının daha düşük olması nedeniyle tercih edilmektedir. Bu yazıda çocuk hastalarda SIG kullanımı ile ilgili güncel bilgiler özetlenmiştir

Anahtar Kelimeler

Subkutan immünglobülin, çocuk, tedavi

Subcutaneous Immunoglobulin Use in Children

Öz

Human plasma derived immunoglobulin products have been considered among treatment options for many of the disor- ders, particularly primary immune deficiencies. Immunoglobulins can be administered either intravenous IV , subcutaneous SC or intramuscular IM route. In recent years, SCIG use has been preferred increasingly because of higher patient comfort, with decreased systemic side effects and costs. Up-to-date information regarding SCIG use in pediatric patients is being summarized in this review

Anahtar Kelimeler

Subcutaneous immunoglobulin, children, treatment

Kaynakça

• Bruton oc. Agammaglobulinemia. Pediatrics 1952;9:722-8.
• Jolles S. Subcutaneous and intramuscular immune globulin therapy. www.uptodate.com.
• Janeway CA, Apt l, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians 1953;66:200-2.
• Gitlin D, Janeway CA. Agammaglobulinemia: conge- nital, acquired and transient forms. Prog Hematol 1956;1:318-56.
• Hill lE, Mollison Pl. MRC working party on hypo- gammaglobulinemia, collection of cases and design of trial, Chap. II, Hypogammaglobulinemia in the UK. Her Majesty’s Stationery Office: London, 1971: pp. 4-8.
• Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008;28:779.
• https://doi.org/10.1016/j.iac.2008.07.002
• Stiehm ER. Adverse effects of human immunoglobu- lin therapy. Transfus Med Rev 2013;27:171.
• https://doi.org/10.1016/j.tmrv.2013.05.004
• Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy 2014;6:71-83.
• https://doi.org/10.2217/imt.13.146
• Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: A retrospective cohort study. PLoS One 2016;11: e0159993.
• https://doi.org/10.1371/journal.pone.0159993
• Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglo- bulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011;16:92-7.
• https://doi.org/10.1111/j.1529-8027.2011.00330.x
• US Food and Drug Administration (FDA) approval: http://www.fda.gov/biologicsbloodvaccines/bloodblo- odproducts/approvedproducts/licensedproductsblas/ fractionatedplasmaproducts/ucm414117.htm (Accessed on September 19, 2014).
• Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734.
• https://doi.org/10.1007/s10875-010-9423-4
• Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunog- lobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265.
• https://doi.org/10.1007/s10875-006-9021-7
• Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio Drugs 2007;21:105.
• https://doi.org/10.2165/00063030-200721020-00005
• Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a revi- ew of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525.
• https://doi.org/10.1016/j.jaci.2006.01.015
• Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008;28:803.
• https://doi.org/10.1016/j.iac.2008.06.006
• Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in pati- ents with primary immunodeficiencies. Clin Immunol 2011;139:133.
• https://doi.org/10.1016/j.clim.2011.01.006
• Waniewski J, Gardulf A, Hammarström l. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunode- ficiency. J Clin Immunol 1994;14:90.
• https://doi.org/10.1007/BF01541341
• Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in pati- ents with primary immunodeficiencies. Clin Immunol 2011;139:133.
• https://doi.org/10.1016/j.clim.2011.01.006
• Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglo- bulin for primary immunodeficiency in the United States. J Clin Immunol 2013;33:49.
• https://doi.org/10.1007/s10875-012-9776-y
• Kobrynski l. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodefici- ency diseases. Biologics 2012;6:277-87.
• https://doi.org/10.2147/BTT.S25188
• Jolles S, Orange JS, Gardulf A, et al. Current treat- ment options with immunoglobulin G for the individu- alization of care in patients with primary immunodefi- ciency disease. Clin Exp Immunol 2015;179:146.
• https://doi.org/10.1111/cei.12485
• Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122:210.
• https://doi.org/10.1016/j.jaci.2008.04.044
• Gardulf A, nicolay U, Asensio O, et al. Rapid subcu- taneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies- -a prospective, multi-national study. J Clin Immunol 2006;26:177.
• https://doi.org/10.1007/s10875-006-9002-x
• Markvardsen lH, Christiansen I, Andersen H, Jakobsen J. Headache and nausea after treatment with high-dose subcutaneous versus intravenous immuno- globulin. Basic Clin Pharmacol Toxicol 2015;117:409- 12.
• https://doi.org/10.1111/bcpt.12428
• Epstein JS, Zoon KC. Dear doctor letter - important drug warning: immune globulin intravenous (human). FDA Med Watch. US Food and Drug Administration; 1998.
• Pierce lR, Jain n. Risks associated with the use of intravenous immunoglobulin. Transfusion Med Rev 2003;17:241-51.
• https://doi.org/10.1016/S0887-7963(03)00038-5
• Fasth A, nystrom J. Safety and efficacy of subcutane- ous human immunoglobulin in children with primary immunodeficiency. Acta Paediatrica 2007;96:1474-8.
• https://doi.org/10.1111/j.1651-2227.2007.00485.x
• Sundin U, nava S, Hammarstrom l. Induction of unresponsiveness against IgA in IgA- deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112:341-6.
• https://doi.org/10.1046/j.1365-2249.1998.00571.x
• Karakoç Aydıner E, Kıykım A, Barıs S, Özen A, Barlan I. Use of subcutaneous immunoglobulin in primary immune deficiencies. Turk Pediatri Ars 2016;51:8-14.
• https://doi.org/10.5152/TurkPediatriArs.2016.3058
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei n. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody defi- ciencies: systematic review and meta-analysis. J Clin Immunol 2012;32:1180-92.
• https://doi.org/10.1007/s10875-012-9720-1
• Bonilla FA, Duff C. Subcutaneous Immunoglobulin Replacement. Immune Deficiency Foundation: Clinical Focus 2015;16:1-16.